Business
Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026
SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will present new data at the American Association of Cancer Research (AACR) annual meeting in San Diego, California from April 17-22, 2026. The Company will demonstrate new data on its approach of simultaneously activating T-cells while inducing the expression of T-cell engagers specifically
About this update from Calidi Biotherapeutics, Inc.
[{"type":"image","alt":"Calidi Biotherapeutics, Inc","displaySize":"","headline":null,"caption":"Calidi Biotherapeutics, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":93,"url":"https://media.zenfs.com/en/globenewswire.com/8983e19176ab43568fb63e4ece5ad7a1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wX9t4eJfVQL9R1_CtWiapg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMA--/https://media.zenfs.com/en/globenewswire.com/8983e19176ab43568fb63e4ece5ad7a1","width":300,"height":93}},"lazy":false},{"type":"text","content":"SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will present new data at the American Association of Cancer Research (AACR) annual meeting in San Diego, California from April 17-22, 2026. The Company will demonstrate new data on its approach of simultaneously activating T-cells while inducing the expression of T-cell engagers specifically in situ in the tumor microenvironment (TME).","length":545,"tagName":"p"},{"type":"text","content":"RedTail is Calidi’s systemically delivered virotherapy platform designed to selectively target tumors, remodel the TME, and enable high-level expression of therapeutic genetic payloads directly at the tumor site while limiting peripheral exposure. CLD-401, the lead candidate derived from the RedTail platform, is engineered to express high levels of IL-15 SA, a known T and NK-cell activator, in the TME. The Company expects to file an IND for CLD-401 by the end of 2026.","length":472,"tagName":"p"},{"type":"text","content":"Data presented at the AACR meeting will showcase RedTail viruses that can express both a functional T-cell engager, capable of binding targeted solid tumor cells, and IL-15 SA at high concentrations, allowing for simultaneous T-cell activation and high expression in situ of a T-cell engager. T-cell engagers have shown exceptional efficacy in hematological malignancies but have failed to show clinical benefit in solid tumors where the TME inhibits immune cell infiltration and T-cell activity. By remodeling the TME and driving T-cell activation in concert with expression of a T-cell engager, RedTail may overcome these historical limitations.","length":647,"tagName":"p"},{"type":"text","content":"Th...